Market participants were significantly less active in early 2023 than during the rush demand in the spring of 2022. However, both inflation rates and stable household incomes now allow us to make optimistic industry growth forecasts, at least in the short term.
On June 8, at the Eurasia – Our Home exhibition, GEROPHARM and Karaganda Pharmaceutical Plant signed a long-term contract to localize the production of...
JSC “Pharmstandard” informs about the change to the membership of the Company's management and the appointment of Dmitry Ivanovich Zaytsev as Chief Executive Officer.
Potapov...
The Ministry of Health of the Russian Federation has authorized the first Russian originator for the treatment of multiple sclerosis developed by the scientists of...
In February 2023, Russian manufacturers produced 100.1 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 12.6% from February 2022, -...